Kymera Perspectives

For Kymera, progress has always meant challenging convention. Over the past decade, the company has helped define an entirely new therapeutic modality, targeted protein degradation, while building the strategies, capabilities, and culture to turn bold science into medicines for patients around the world.

Following Kymera’s 10-year milestone, Founder and CEO, Nello Mainolfi, reflects on the journey from founding vision to clinical validation, and what it will take to deliver a new generation of oral medicines.